Use of abacavir and risk of cardiovascular disease among HIV-infected individuals

Journal of Acquired Immune Deficiency Syndromes

Volumn 71, Issue 4, 2016, Pages 413-419

  Marcus, Julia L ^a   Neugebauer, Romain S ^a   Leyden, Wendy A ^a   Chao, Chun R ^b   Xu, Lanfang ^b   Quesenberry, Charles P ^a   Klein, Daniel B ^b   Towner, William J ^c   Horberg, Michael A ^b   Silverberg, Michael J ^a  

^a DIVISION OF RESEARCH   (United States)

^b KAISER PERMANENTE   (United States)

^c LOS ANGELES MEDICAL CENTER   (United States)

Author keywords

Abacavir; Antiretroviral therapy (ART); Cardiovascular disease; Human immunodeficiency virus (HIV)

Indexed keywords

ABACAVIR; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ALCOHOL CONSUMPTION; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONFERENCE PAPER; DEATH; DEMOGRAPHY; DIABETES MELLITUS; DRUG USE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENTION TO TREAT ANALYSIS; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; OBESITY; PRIORITY JOURNAL; PROPENSITY SCORE; SENSITIVITY ANALYSIS; SMOKING; UNITED STATES; CALIFORNIA; CHEMICALLY INDUCED; COMPLICATION; HIV INFECTIONS; MIDDLE AGED; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; CALIFORNIA; CARDIOVASCULAR DISEASES; DIDEOXYNUCLEOSIDES; HIV INFECTIONS; HUMANS; MIDDLE AGED; RISK FACTORS;

EID: 84960320646     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000881     Document Type: Conference Paper

References (58)

1. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8:e81355.
2. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011;53: 1130-1139.
3. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614-622.
4. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506-512.
5. Marcus JL, Leyden WA, Chao CR, et al. HIV infection and incidence of ischemic stroke. AIDS. 2014;28:1911-1919.
6. Silverberg MJ, Leyden WA, Xu L, et al. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr. 2014;65:160-166.
7. Lo J, Plutzky J. The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patients. J Infect Dis. 2012;205(suppl 3):S368-S374.
8. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62.
9. Tesoriero JM, Gieryic SM, Carrascal A, et al. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14:824-835.
10. Bavinger C, Bendavid E, Niehaus K, et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One. 2013;8:e59551.
11. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479-2486.
12. Klein D, Hurley LB, Quesenberry CP Jr, et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30:471-477.
13. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356: 1723-1735.
14. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: a:D study: a multi-cohort collaboration. Lancet. 2008;371:1417-1426.
15. Obel N, Farkas DK, Kronborg G, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med. 2010;11: 130-136.
16. Lundgren JD, Neuhaus J, Babiker A, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17-F24.
17. Desai M, Joyce V, Bendavid E, et al. Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population. Clin Infect Dis. 2015;61:445-452.
18. Brouwer ES, Napravnik S, Eron JJ Jr, et al. Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients. Epidemiology. 2014;25:406-417.
19. Choi AI, Vittinghoff E, Deeks SG, et al. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS. 2011;25:1289-1298.
20. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009;49:1591-1601.
21. Young J, Xiao Y, Moodie EE, et al. The effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2015;69:413-421.
22. Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis. 2011;52:929-940.
23. Bedimo RJ, Westfall AO, Drechsler H, et al. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis. 2011;53:84-91.
24. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010;170:1228-1238.
25. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS. 2011;25:1993-2004.
26. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009;51:20-28.
27. Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 2012;61:441-447.
28. Post FA, Campbell LJ. Abacavir and increased risk of myocardial infarction. Lancet. 2008;372:803; author reply 804-805.
29. Aberg JA, Ribaudo H. Cardiac risk: not so simple. J Infect Dis. 2010; 201:315-317.
30. Choi AI, Li Y, Deeks SG, et al. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010;121:651-658.
31. Horberg M, Tang B, Towner W, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2010;53:62-69.
32. Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15:615-625.
33. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2551-2559.
34. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed December 4, 2014.
35. Coady SA, Sorlie PD, Cooper LS, et al. Validation of death certificate diagnosis for coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. J Clin Epidemiol. 2001;54:40-50.
36. Elliott MN, Fremont A, Morrison PA, et al. A new method for estimating race/ethnicity and associated disparities where administrative records lack self-reported race/ethnicity. Health Serv Res. 2008;43: 1722-1736.
37. Fiscella K, Fremont AM. Use of geocoding and surname analysis to estimate race and ethnicity. Health Serv Res. 2006;41:1482-1500.
38. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
39. Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA. 2015;313:837-846.
40. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561-570.
41. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550-560.
42. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168:656-664.
43. Moore KL, Neugebauer R, van der Laan MJ, et al. Causal inference in epidemiological studies with strong confounding. Stat Med. 2012;31: 1380-1404.
44. Chaix B, Evans D, Merlo J, et al. Commentary: weighing up the dead and missing: reflections on inverse-probability weighting and principal stratification to address truncation by death. Epidemiology. 2012;23: 129-131; discussion 132-127.
45. Logan R, Tchetgen Tchetgen EJ, Hernan MA. Structural Models for Survival Analysis in SAS: The MSM Macro. 2014. Available at: http://www.hsph.harvard.edu/causal/software/. Accessed February 27, 2015.
46. Sturmer T, Jonsson Funk M, Poole C, et al. Nonexperimental comparative effectiveness research using linked healthcare databases. Epidemiology. 2011;22:298-301.
47. Shlay JC, Visnegarwala F, Bartsch G, et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to dida-nosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr. 2005;38:147-155.
48. Martinez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349: 1036-1046.
49. McComsey GA, Kitch D, Daar ES, et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS. 2012;26:1371-1385.
50. Hsue PY, Hunt PW, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS. 2009;23:2021-2027.
51. Baum PD, Sullam PM, Stoddart CA, et al. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS. 2011;25:2243-2248.
52. Satchell CS, O'Halloran JA, Cotter AG, et al. Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy. J Infect Dis. 2011;204:1202-1210.
53. Martinez E, Larrousse M, Podzamczer D, et al. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS. 2010;24:F1-F9.
54. Wohl DA, Arnoczy G, Fichtenbaum CJ, et al. Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther. 2014;19:141-147.
55. 2010 Quarterly HIV/AIDS Statistics. 2010. Available at: http://www. cdph.ca.gov/data/statistics/Pages/OA2010QtrlyStats.aspx. Accessed May 4, 2015.
56. Koebnick C, Langer-Gould AM, Gould MK, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J. 2012;16:37-41.
57. Gordon N. Similarity of the Adult Kaiser Permanente Membership in Northern California to the Insured and General Population in Northern California: Statistics from the 2011 California Health Interview Survey. 2015. Available at: http://www.dor.kaiser.org/external/chis-non-kp- 2011/. Accessed August 24, 2015.
58. Klein DB, Leyden WA, Xu L, et al. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care. Clin Infect Dis. 2015;60:1278-1280.